KRTX Karuna Therapeutics Inc

Price (delayed)

$123.77

Market cap

$3.66B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.88

Enterprise value

$3.32B

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and ...

Highlights
The equity has surged by 51% year-on-year but it has declined by 4.2% since the previous quarter
The net income has plunged by 153% YoY and by 19% from the previous quarter
The company's quick ratio fell by 42% YoY and by 39% QoQ

Key stats

What are the main financial stats of KRTX
Market
Shares outstanding
29.55M
Market cap
$3.66B
Enterprise value
$3.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$107.72M
EBITDA
-$107.47M
Free cash flow
-$96.77M
Per share
EPS
-$3.88
Free cash flow per share
-$3.28
Book value per share
$19.02
Revenue per share
$0
TBVPS
$19.58
Balance sheet
Total assets
$577.19M
Total liabilities
$16.85M
Debt
$8.4M
Equity
$560.34M
Working capital
$556.79M
Liquidity
Debt to equity
0.01
Current ratio
55.01
Quick ratio
52.76
Net debt/EBITDA
3.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-22.9%
Return on equity
-23.4%
Return on invested capital
-40.2%
Return on capital employed
-19%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRTX stock price

How has the Karuna Therapeutics stock price performed over time
Intraday
0.72%
1 week
3.87%
1 month
7.88%
1 year
60.97%
YTD
21.83%
QTD
1.18%

Financial performance

How have Karuna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$108.43M
Net income
-$107.76M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 153% YoY and by 19% from the previous quarter
The operating income has dropped by 132% year-on-year and by 18% since the previous quarter

Growth

What is Karuna Therapeutics's growth rate over time

Valuation

What is Karuna Therapeutics stock price valuation
P/E
N/A
P/B
6.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KRTX's EPS is down by 15% since the previous quarter
The equity has surged by 51% year-on-year but it has declined by 4.2% since the previous quarter
The price to book (P/B) is 3.3% more than the last 4 quarters average of 6.3

Efficiency

How efficient is Karuna Therapeutics business performance
Karuna Therapeutics's return on equity has shrunk by 80% YoY and by 7% QoQ
The return on assets has dropped by 79% year-on-year and by 7% since the previous quarter
Karuna Therapeutics's ROIC has plunged by 73% YoY and by 21% from the previous quarter

Dividends

What is KRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRTX.

Financial health

How did Karuna Therapeutics financials performed over time
KRTX's total liabilities has soared by 180% YoY and by 102% from the previous quarter
The total assets has surged by 53% year-on-year but it has declined by 2.7% since the previous quarter
The debt is 99% smaller than the equity
The equity has surged by 51% year-on-year but it has declined by 4.2% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.